一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Ribociclib；Letrozole；Ansastrozole；Goserelin；Leuprolide；Exemestane，当前状态为招募中。登记地点显示中国北京、广州、哈尔滨、郑州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ribociclib；Letrozole；Ansastrozole；Goserelin；Leuprolide；Exemestane · III 期
登记条件中文摘要
年龄范围：18岁至100岁
登记的基本范围为不限性别，年龄18岁至100岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记摘要未单独列出可展示的排除条件，请查看英文原文并向研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Novartis Investigative Site · 北京
- Novartis Investigative Site · 广州
- Novartis Investigative Site · 哈尔滨
- Novartis Investigative Site · 郑州
- Novartis Investigative Site · 南京
- Novartis Investigative Site · 南昌
- Novartis Investigative Site · 长春
- Novartis Investigative Site · 济南
- Novartis Investigative Site · 济宁
- Novartis Investigative Site · 成都
- Novartis Investigative Site · 乌鲁木齐
- Novartis Investigative Site · 杭州
- Novartis Investigative Site · 温州
- Novartis Investigative Site · 北京
- Novartis Investigative Site · 广州
- Novartis Investigative Site · 青岛
- Novartis Investigative Site · 上海
- Novartis Investigative Site · 石家庄
- Novartis Investigative Site · 天津
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- Key Inclusion criteria:
- * Participant is an adult, male or female ≥ 18 years of age at the time of informed consent form signature (IC).
- * Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer (BC) based on the most recently analyzed tissue sample tested by a local laboratory prior to enrollment.
- * Participant has HER2- BC defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing based on the most recently analyzed tissue sample.
- * Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and participants should have at least 3 years remaining of endocrine adjuvant therapy.
- * For participants with prior ET treatment \> 12 months, restaging is highly recommended (unless contradictory to local regulations) to rule out disease recurrence prior to enrollment.
- * The number of participants with prior ET between 12 and 36 months will be capped at 30%. The cap will not apply to Black or African American participants.
- * Participant has no contraindication to receive adjuvant ET in the study.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05827081；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。